Belgium pharmaceutical giant UCB is extending its 340B contract pharmacy restrictions to all federal grantees and adding new data submission [...] …
Articles by : William Newton, Associate Editor/Senior Writer
A Washington state hospital on Tuesday became the fifth provider to sue the federal government for authorizing Johnson & Johnson [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Four drugmakers are urging a federal appeals court to affirm a lower court’s decision to dismiss a California health system’s [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The growth in total 340B purchases last year was largely a result of drugmaker price increases and broader healthcare trends, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drug purchases under the 340B program reached $66.3 billion in 2023, marking a 24% increase over the $54 billion in [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A political action committee (PAC) that funded efforts opposing state 340B contract pharmacy access bills through misleading claims linking the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Pharmaceutical Research and Manufacturers of America (PhRMA) expressed “serious concerns” with the federal government’s opposition to Johnson & Johnson’s (J&J’s) [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Federal regulators’ inaction on the 340B program’s interactions with Medicare drug price negotiations will likely lead drugmakers to pursue “manufacturer-friendly” [...] …
